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INTRODUCTION
The involvement of axillary lymph nodes (LNs) is the most 
important prognostic factor in operable primary breast cancer 
and is strongly associated with both disease-free and overall 
survival [1,2]. After curative breast surgery, the involvement 
of axillary nodes is examined to determine the use of adjuvant 
systemic therapy, which is strongly indicated in patients with 
axillary LN metastases. The absolute number of nodes involved 
is also considered when deciding on the use of radiotherapy 
according to current guidelines based on the tumor-node-
metastasis system; for example, if a patient has a pT2N1M0 
cancer, radiation therapy is frequently omitted after modified 
radical mastectomy (MRM), even in node positive breast can-
cer patients. The field of radiation therapy is also influenced 
by the number of involved nodes; where four or more axillary 
LNs are involved, the radiation field is extended to include the 
supraclavicular area. Hence, radiation oncologists have severe 
doubts as to whether the absolute number of positive nodes is 
a suitable criterion for assessing the axillary nodal status to 
guide therapeutic choices and predict the prognosis of breast 
cancer patients.
Lymph node status is assessed by axillary lymph node dissec-
tion (ALND) and, often in daily practice, the extent of axillary 
dissection varies according to the surgeon. There is also het-
erogeneity in node examination. The Comprehensive Cancer 
Center North-Netherlands (CCCN) reviewed 4,806 axillary 
dissections. The number of reported positive nodes varied sig-
nificantly between pathology laboratories. Generally, a more 
extensive surgical axillary dissection or histopathologic exam-
ination of the specimen resulted in a higher number of positive 
nodes [3].
Several authors have noted this confusion and have suggested 
the use of a proportion or percentage of involved nodes [4]. A 
growing number of studies have found that a ratio-based clas-
sification of node involvement is a superior prognostic factor 
than the absolute numbers of involved nodes in breast cancer 
[4-11]. To evaluate this issue, we examined the impact of the 
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Purpose: This study evaluated the prognostic impact of the 
lymph node ratio (LNR; i.e., the ratio of positive to dissected 
lymph nodes) on recurrence and survival in breast cancer patients 
with positive axillary lymph nodes (LNs). Methods: The study     
cohort was comprised of 330 breast cancer patients with posi-
tive axillary nodes who received postoperative radiotherapy       
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years. By minimum p-value approach, 0.25 and 0.55 were the 
cutoff values of LNR at which most significant difference in DFS 
and DSS was observed. The DFS and DSS rates correlated sig-
nificantly with tumor size, pN classification, LNR, histologic grade, 
lymphovascular invasion, the status of estrogen receptor and pro-
gesterone receptor. The LNR based classification yielded a statis-
tically larger separation of the DFS curves than pN classification. 
In multivariate analysis, histologic grade and pN classification 
were significant prognostic factors for DFS and DSS. However, 
when the LNR was included as a covariate in the model, the LNR 
was highly significant (p<0.0001), and pN classification was not 
statistically significant (p>0.05). Conclusion: The LNR predicts 
recurrence and survival more accurately than pN classification in 
our study. The pN classification and LNR should be considered 
together in risk estimates for axillary LNs positive breast cancer 
patients.
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number of positive nodes, the number of dissected nodes and 
the proportion of involved nodes among all dissected nodes, 
i.e., the lymph node ratio (LNR), on recurrence and survival 
in breast cancer after other known prognostic factors had been 
taken into account.
METHODS
Patient population and treatment methods
The patients in this study were identified from a database of 
patients who received postoperative radiotherapy in Yeouido 
St. Mary’s Hospital between 1987 and 2004. Eligible patients 
were those with primary breast cancer with positive axillary 
LNs after adequate ALND. Three hundred thirty females were 
enrolled in this study. None of the patients had evidence of dis-
tant metastases at the time of diagnosis, and all underwent 
breast conserving surgery or MRM including at least level l-ll 
ALND. The adjuvant treatment was a combination of chemo-
therapy, hormonal therapy and radiotherapy. The adjuvant treat-
ment was done after operation and none of patients received 
neoadjuvant chemotherapy. The external beam radiation ther-
apy was done in all patients using photon or electron beams. 
The ipsilateral breast or chestwall was irradiated. When 4 or 
more positive axillary nodes were presented, supraclavicular 
area was also treated. The internal mammary area was treated 
when preoperative radiological imaging defined the involve-
ment of internal mammary LN. The Institutional Review Board 
of Yeouido St. Mary’s Hospital approved this retrospective study 
(The number of approval: SC10RESI0019).
Prognostic variables
In each patient, the following data were available from the 
medical records: age, menopausal status, type of operation, 
chemotherapeutic agents, hormonal and radiotherapy and 
pathology reports on the surgical specimen. The tumor factors 
analyzed were the histologic type, histologic grade, tumor size, 
the status of margin, lymphovascular invasion, the status of 
estrogen receptor (ER), progesterone receptor (PR) and c-erbB2 
receptor. The LN factors analyzed were the number of positive 
axillary nodes, the number of dissected nodes and the LNR. 
The pathologic stage was classified according the 6th edition 
of the American Joint Committee on Cancer (AJCC) staging 
manual [12].
The treatment outcomes were also evaluated. Local recur-
rence means recurrence in the ipsilateral breast or chest wall. 
Regional recurrence means recurrence in ipsilateral axillary, 
supraclavicular, infraclavicular or internal mammary nodes. 
The survival end event was defined as death from breast cancer.
Statistical analyses
Univariate analyses of survival were performed by the method 
of Kaplan and Meier. The curves for locoregional recurrence-
free survival (LRRFS), distant metastasis-free survival (DMFS), 
disease-free survival (DFS) and disease-specific survival (DSS) 
were plotted. The significance of outcome differences was com-
pared by the log-rank test.
After ascertaining that the LNR was significantly associated 
with DFS and DSS, various LNR cutoffs were evaluated, rang-
ing from 0.05 to 0.95 at intervals of 0.05, by the minimum p-
value approach. We selected cutoff points at which the most 
significant difference in DFS and DSS was observed. The num-
ber of dissected nodes was also evaluated in the same way to 
find the most significant cutoff value that correlated with recur-
rence and survival.
Multivariate analysis was performed using Cox proportional 
hazard modeling with or without LNR as a covariate. A p-value 
of less than 0.05 was considered significant. Analyses were per-
formed with SAS software version 9.1 (SAS Institute Inc., Cary, 
USA). 
RESULTS
The median follow up was 7.5 years (range, 0.3-21.8 years). 
Table 1 summarizes the data on tumor and treatment charac-
teristics of this study. The median age was 45 years (range, 23-
77 years). The median number of nodes removed was 18 (range, 
7-61 years). Most patients (95.5%) had at least 10 axillary LNs 
removed. The median number of involved nodes was 4 (range, 
1-43). The median LNR was 0.28 (range, 0.03-1). Among 330 
patients, adjuvant systemic therapy was completed in 328 pa-
tients (chemotherapy alone, 38.8%; hormone therapy alone, 
3.9%; both chemotherapy and hormone therapy, 56.7%). The 
current treatment guideline consists of chemotherapy +/- 
trastuzumab +/- hormone therapy depending on hormone- 
and c-erbB2 receptor status. However, the status of c-erbB2 
receptor was not routinely examined before 2000 in our insti-
tution and trastuzumab could not be considered for adjuvant 
therapy in this study period. All patients completed the course 
of radiotherapy. The median dose of radiation therapy was 
50.4 Gy (range, 50.4-64.8 Gy).
Recurrence and survival outcomes
Overall, 28 patients (8.5%) experienced local recurrence, and 
8 patients (2.4%) experienced regional recurrence. The com-
bined LRR rate was 10.9% (n=36 patients). DM occurred in 
133 patients (40.3%). The corresponding 10-year Kaplan-Meier 
estimates (±standard error) were 89.2±1.7% for LRRFS and 
62.3±2.7% for DMFS. The 10-year Kaplan-Meier DFS and DSS 206   Ji-Yoon Kim, et al.
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were 60.0±2.7% and 55.5±3.4%, respectively.
Cutoff values for LNR and dissected nodes
By the minimum p-value approach, 0.25 and 0.55 were select-
ed as the most significant LNR levels correlating with DFS and 
DSS (p<0.0001). The patients were classified into three groups: 
patients with LNR≤0.25, LNR 0.26-0.55, and LNR>0.55, which 
represented 48.2%, 24.8%, and 27.0% of the study cohort, re-
spectively. With respect to the numbers of dissected nodes, we 
could not find any value that correlated significantly with DFS 
and DSS in this study.
Univariate analysis
Table 2 presents the comparisons of 10-year Kaplan-Meier 
LRRFS, DMFS, DFS, and DSS stratified by various prognostic 
factors. The LNR based classification was tested to predict the 
treatment outcome and survival. The LRRFS decreased with 
higher numbers of positive nodes and PR-negative status. The 
status of margin was not correlated with the LRRFS. The DMFS 
decreased with larger tumor size, higher number of positive 
nodes, higher LNR, higher histologic grade and PR-negative 
status. Larger tumor size, higher number of positive nodes, 
higher LNR, higher histologic grade, presence of lymphovas-
cular invasion and PR-negative status were associated with 
decreased DFS and DSS. ER-negative status was correlated 
with decreased DSS but not with DFS.
Analysis of survival outcome by pN classification vs. LNR
The univariate Kaplan-Meier DFS estimates were compared 
between the groups defined by pN staging (Figure 1A) or by 
Table 1. Clinical and pathologic features of the patients
Characteristics   No. (%)   
Age (yr)* 45 (23-77)
   ≤45    181 (54.9)
   >45    149 (45.1)
Menopausal status
   Premenopause    184 (55.8)
   Postmenopause    136 (41.2)
   Unknown    10 (3.0)
Histology
   Invasive ductal    308 (93.3)
   Invasive lobular      9 (2.7)
   Medullary      7 (2.1)
   Mucinous      2 (0.6)
   Other      4 (1.2)
Tumor size (cm)
   ≤2       60 (18.8)
   >2, ≤5     194 (58.8)
   >5       76 (23.2)
No. of positive nodes
   1-3    140 (42.4)
   4-9    108 (32.7)
   ≥10      82 (24.8)
No. of dissected nodes
   Median 18
   ≤15    121 (36.7)
   >15    209 (63.3)
Histologic grade
   l    13 (3.9)
   II    119 (36.1)
   III      66 (20.0)
   Unknown 132 (40)
Lymphovascular invasion
   Yes    195 (59.1)
   No    13 (3.9)
   Unknown 122 (37)
BCS=breast conserving surgery; MRM=modified radical mastectomy; Scl=supraclavicular area; IM=internal mammary. 
*Median (range).
Characteristics   No. (%)
Margin status
   Positive    13 (3.9)
   Close      8 (2.4)
   Negative     309 (93.6)
Estrogen receptor
   Positive     114 (34.5)
   Negative       97 (29.4)
   Unknown     119 (36.1)
Progesterone receptor
   Positive    127 (28.5)
   Negative      84 (25.5)
   Unknown    119 (36.1)
C-erbB2 receptor
   Positive      80 (24.2)
   Negative      38 (11.5)
   Unknown    212 (64.2)
Type of surgery
   BCS    113 (34.2)
   MRM    217 (65.8)
Radiotherapy
   Breast      85 (25.8)
   Breast+Scl    16 (4.8)
   Chestwall+Scl    196 (59.4)
   Chestwall+Scl+IM      33 (10.0)
Chemotherapy
   Yes     315 (95.5)
   No     15 (4.5)
Hormone therapy
   Yes    200 (60.6)
   No    130 (39.4)Prognostic Significance of Axillary Lymph Node Ratio 207
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Table 2. Ten-year Kaplan-Meier locoregional recurrence-free survival, distant metastasis-free survival, disease-free survival, disease-specific survival 
according to the prognostic factors
Variable No. of patients
10-yr Kaplan-Meier estimates±SE (%)
  10-yr LRRFS   10-yr DMFS 10-yr DFS 10-yr DSS
Age (yr)
   ≤45
   >45
   p-value
 
181
149
 
  90.6±2.2
  87.1±2.8
0.3268
 
59.4±3.7
58.2±4.3
0.7075
 
58.1±3.8
53.6±4.3
0.3434
 
63.0±3.8
56.7±4.4
0.2113
Menopausal status
   Premenopause
   Postmenopause
   p-value
 
184
136
 
  89.6±2.3
  87.3±2.9
0.5481
 
61.0±3.7
56.0±4.5
0.3110
 
58.7±3.7
52.3±4.5
0.2305
 
64.0±3.7
55.3±4.6
0.1023
Tumor size (cm)
   ≤2 
   >2, ≤5 
   >5 
   p-value
 
  60
194
  76
 
  93.2±3.3
  88.0±2.4
  88.2±3.7
0.3567
 
76.0±5.6
62.2±3.6
37.8±5.8
<0.0001
 
73.6±6.0
59.5±3.7
34.3±5.6
<0.0001
 
75.3±5.9
63.7±3.7
40.5±5.8
<0.0001
Margin status
   Positive
   Close
   Negative 
   p-value
 
  13
    8
309
 
    84.6±10.0
100.0±0.0 
  88.9±1.7
0.9142
 
  41.0±19.0
  70.0±18.2
59.0±2.9
0.7942
 
  41.0±19.0
60.0±1.8
56.3±2.9 
0.8727
 
  61.5±13.5
  87.5±11.7
59.8±3.0
0.7115
No. of positive nodes
   1-3
   4-9
   ≥10
   p-value
 
140
108
  82
 
  92.1±2.3
  90.4±2.9
  81.7±4.3
0.0206
 
71.7±4.1
59.5±4.8
36.6±5.5
<0.0001
 
68.6±4.2
57.4±4.9
33.1±5.3
<0.0001
 
74.8±3.9
58.8±5.1
37.9±5.6
<0.0001
Lymph node ratio
   0-0.25
   0.26-0.55
   0.56-1
   p-value
 
159
  82
  89
 
  92.5±2.1
  85.0±4.0
  86.5±3.6
0.1082
 
73.3±3.7
60.9±5.6
31.8±5.0
<0.0001
 
71.2±3.8
57.0±5.7
28.5±4.9
<0.0001
 
74.5±3.7
62.3±5.7
33.5±5.3
<0.0001
No. of dissected nodes
   ≤15
   >15
   p-value
 
121
209
 
  88.0±3.0
  88.9±2.2
0.8632
 
57.5±4.7
60.1±3.6
0.6538
 
54.9±4.7
57.1±3.6
0.5418
 
59.7±4.8
60.1±3.6
0.9329
No. of dissected nodes
   ≤20
   >20
   p-value
 
261
  69
 
  89.0±2.6
  89.1±2.3
0.9202
 
59.0±4.3
58.8±3.7
0.8290
 
56.5±4.3
55.9±3.8
0.7326
 
59.7±4.4
60.6±3.8
0.8957
Histologic grade
   I
   II
   III
   p-value
 
  13
119
  66
 
  92.3±7.4
  87.1±3.1
  96.4±4.2
0.6360
 
  84.6±10.0
61.9±4.9
46.5±6.2
0.0017
 
  84.6±10.1
58.0±5.0
43.5±6.2
0.0015
 
  84.6±10.0
66.6±4.7
43.6±6.8
0.0013
Lymphovascular invasion
   Yes
   No
   p-value
 
195
  13
 
  88.0±2.4
  92.3±7.4
0.6440
 
56.3±3.8
 84.6 ±10.0
0.0806
 
53.8±3.8
  84.6±10.0
0.0566
 
57.5±3.9
92.3±7.4
0.0397
Estrogen receptor
   Positive 
   Negative 
   p-value
 
114
  97
 
  90.9±2.8
  87.6±3.3
0.3768
 
64.7±4.9
57.1±5.1
0.0851
 
60.4±5.0
55.7±5.0
0.1525
 
71.4±4.7
55.3±5.5
0.0067
Progesterone receptor
   Positive
   Negative
   p-value
 
127
  84
 
  94.3±2.1
  81.9±4.2
0.0038
 
65.8±4.6
54.4±5.5
0.0267
 
61.9±3.8
52.4±5.5
0.0177
 
72.4±4.4
50.7±6.0
0.0019
c-erbB2 receptor
   Positive
   Negative
   p-value
 
  80
  38
 
  86.5±4.0
  97.4±2.6
0.0918
 
63.4±6.0
68.0±7.7
0.8286
 
57.0±6.7
65.3±7.8
0.6581
 
68.0±6.7
71.9±7.8
0.9473
SE=standard error; LRRFS=locoregional recurrence-free survival; DMFS=distant metastasis-free survival; DFS=disease-free survival; DSS=disease-specific survival.208   Ji-Yoon Kim, et al.
http://ejbc.kr  http://dx.doi.org/10.4048/jbc.2011.14.3.204
LNR (Figure 1B). The groups categorized by LNR yielded a 
significantly larger separation of the DFS curves compared 
with pN staging. The log-rank χ2 associated with the LNR (p< 
0.0001, log-rank χ2=55.4) was larger than that of pN (p<0.0001, 
log-rank χ2=36.6), indicating a higher significance. Ten-year 
DFS was 71.2±3.8% among patients with LNR ≤0.25, com-
pared with 57.0±5.7% and 28.5±4.9% for those with LNRs of 
0.26-0.55 and >0.55, respectively (p<0.0001). The DSS esti-
mates were also compared between the groups stratified by 
pN staging (Figure 1C) or by LNR (Figure 1D). The log-rank 
χ2 associated with the LNR (p<0.0001, log-rank χ2=50.2) was 
larger than that of pN (p<0.0001, log-rank χ2=34.6) and 10-
year DSS was 74.5±3.7% among patients with LNR ≤0.25, 
compared with 62.3±5.7% and 33.5±5.3% for those with 
LNRs of 0.26-0.55 and >0.55, respectively (p<0.0001).
In addition, for stage III patients, the LNR based classifica-
tion can distinguish subgroups more accurately than pN stage 
for DFS and DSS (Figure 2). The statistical power of the LNR 
based classification (p<0.0001, log-rank χ2=25.2) for DFS was 
larger than pN staging classification (p=0.0015, log-rank χ2= 
13.1). The pN classification graphically showed a poorer prog-
nostic separation. The pN1 and pN2 survival curves are close 
to one another (Figure 2A), but the ratio-based curves are dis-
tinct from the early course of follow-up and remain separated, 
even at follow-up exceeding 20 years (Figure 2B). For DSS, 
similar findings were observed that the LNR based classifica-
tion (p<0.0001, log-rank χ2=22.3) showed better stratifica-
tion than the pN classification (p=0.0031, log-rank χ2=11.6). 
Multivariate analysis
Cox regression analysis was performed to evaluate whether 
the LNR was associated with DFS and DSS. The results of mul-
tivariate analyses are presented in Table 3. Histologic grade and 
the number of positive nodes were significant prognostic fac-
tors when the LNR was not included in the analysis. However, 
when the LNR was included in the model as a covariate, the 
D
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Figure 1. Disease-free survival (DFS) and disease-specific survival (DSS) of all patients stratified by pN stage and lymph node ratio (LNR), respectively. 
The LNR based classification (B, D) yields a statistically larger separation of the curves (larger χ2) compared to absolute number of the nodes (A, C).Prognostic Significance of Axillary Lymph Node Ratio 209
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LNR was highly significant (p<0.0001) and the number of 
positive nodes lost its significance (p>0.05). This means that, 
in this analysis, the LNR is a more significant prognostic fac-
tor than the absolute number of nodes.
Survival analysis by LNR in each stage
To determine whether the LNR had a prognostic significance 
on survival in each stage, we performed the survival analysis 
based on the LNR in patients with stage II and stage III, respec-
tively. The LNR had a prognostic impact on DFS in both pa-
tients with stage II (p=0.0392) and stage III (p<0.0001). For 
the patients with stage III, the DSS was also significantly cor-
related with the LNR (p<0.0001). 
The survival outcome was analyzed by the LNR in each pN 
stage. The LNR had a prognostic significance on the DFS and 
DSS in both patients with pN1 and pN2. However, for the pa-
tients with pN3, the LNR was not associated with the survival. 
It might be attributed to that the group with pN3 and the LNR 
≤0.25 consisted of only 1 patient. The results of above analyses 
were presented in Table 4.
DISCUSSION
The lymphatic drainage of the breast moves primarily super- 
iorly and laterally toward the axillary nodes. Lymphatic metas-
tases to the axilla occur in an orderly fashion, with level I pre-
ceding level II, followed by level III. It is relatively uncommon 
to see a patient with level III node involvement in the absence 
of node involvement at lower levels [13]. Therefore, ALND is 
extended to level III nodes only if gross disease is apparent in 
the level I or II nodes.
To accurately stage the axilla, it is commonly recommended 
that ALND should clear the level I and II nodes with at least 
10 nodes sampled. However, the recommendation to examine 
at least 10 nodes suffices only to determine nodal positivity or 
negativity. A mathematical model based on 1,446 complete 
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Figure 2. Disease-free survival (DFS) and disease-specific survival (DSS) of stage lll patients stratified by pN stage and lymph node ratio (LNR) based 
classification, respectively. The LNR based classification (B, D) can distinguish subgroups more clearly than pN stage (A, C).210   Ji-Yoon Kim, et al.
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axillary dissections has suggested that a minimum of 10 nodes 
needs to be removed to have a 93% predictive value that the 
remaining modes are clear [14].
There is a tendency for a higher number of dissected nodes 
to be associated with an increased chance of finding tumor posi- 
tive nodes [3,7,8]. Kuru and Bozgul [15] reported that level I-
III ALND to remove more than 20 nodes is needed for assess-
ing the axillary nodal status by removal of more positive nodes. 
However, extensive ALND may result in pain, numbness, im-
pairment of the range of motion of the shoulder or arm edema, 
all of which severely impair the patients’ quality of life [16]. Thus, 
the extent of ALND has been more limited recently.
This limited extent of axillary dissection combined with radi-
ation therapy was compared with the traditional full ALND. 
In the United Kingdom, axillary node sampling (ANS), which 
is widespread in clinical practice, needs at least four nodes re-
moved from the axillary tail and the lower axillary fat to obtain 
95% accuracy in staging the axilla. In the Edinburgh random-
ized trial, ANS showed a comparable axillary recurrence and 
overall survival with ALND up to level III. For node positive 
patients, the ANS group received postoperative radiotherapy. 
There was no significant difference in axillary recurrence be-
tween ALND and ANS followed by radiotherapy. This sug-
gested that the involved axilla could be effectively treated by 
radiotherapy. Morbidity associated with full ALND was de-
creased in the ANS group. Modern simulation techniques and 
shielding of the shoulder joint and capsule are likely to reduce 
shoulder morbidity after radiotherapy to the axilla [17-19].
Since its recent introduction by Krag et al. [20], the more 
targeted procedure of sentinel lymph node biopsy (SLNB) has 
become a safe and acceptable technique in patients with T1-2 
clinically node negative breast cancer. If a positive sentinel node 
(SN) is found, it is recommended to continue with ALND. Even 
in locally advanced breast cancer, the feasibility and accuracy of 
SLNB has been investigated after neoadjuvant chemotherapy.
Because the absolute number of dissected nodes is decreas-
ing because of the trend to minimize the extent of ALND, phy-
sicians could be concerned about underestimating the real 
number of involved nodes. Thus, an appropriate method to 
assess the nodal status is needed to allow the choice of the cor-
rect adjuvant therapy and predict the treatment outcome.
From the Surveillance, Epidemiology, and End Results (SEER) 
Table 3. Multivariate analysis of disease-free survival and disease-specific survival
Variable
Without LNR as a covariate With LNR as a covariate
DFS DSS DFS DSS
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Histologic grade
   I 0.35 (0.05-2.67) 0.3112 0.49 (0.06-3.87) 0.5040 0.32 (0.04-2.54)    0.2800 0.53 (0.06-4.42) 0.5600
   II 0.59 (0.33-1.05) 0.0713 0.48 (0.25-0.94) 0.0332 0.44 (0.24-0.81)    0.0081 0.41 (0.2-0.8) 0.0099
   III 1 1 1 1
LVI
   No  1 1 1 1
   Yes  1.23 (0.28-5.43) 0.7829   1.94 (0.25-15.28) 0.5298 1.10 (0.24-5.05)    0.9000 1.73 (0.2-14.59) 0.6168
ER
   Negative  1 1 1 1
   Positive  0.79 (0.43-1.47) 0.4615 0.54 (0.25-1.13) 0.1031 0.84 (0.46-1.52)    0.5545 0.57 (0.27-1.20) 0.1387
PR
   Negative 1 1 1 1
   Positive 0.70 (0.38-1.29) 0.2515 0.66 (0.32-1.35) 0.2572 0.55 (0.30-1.03)    0.0610 0.49 (0.23-1.05) 0.0667
Tumor size (cm)
   ≤2  0.56 (0.19-1.67) 0.2940 0.68 (0.21-2.21) 0.5141 0.82 (0.27-2.53)    0.7286 0.82 (0.25-2.67) 0.7384
   >2, ≤5  0.97 (0.47-2.02) 0.9320 0.77 (0.34-1.75) 0.5389 1.09 (0.53-2.24)    0.8211 0.95 (0.43-2.06) 0.8878
   >5  1 1 1 1
Positive lymph node
   1-3 0.32 (0.15-0.69) 0.0035 0.29 (0.11-0.72) 0.0075 2.18 (0.59-8.10)    0.2460 1.86 (0.37-9.40) 0.4525
   4-9 0.55 (0.27-1.13) 0.1055 0.62 (0.28-1.39) 0.2498 1.65 (0.73-3.70)    0.2278 1.64 (0.68-3.95) 0.2726
   ≥10 1 1 1 1
LNR
   0-0.25 0.07 (0.02-0.24) <0.0001 0.08 (0.02-0.34) 0.0006
   0.26-0.55 0.16 (0.07-0.38) <0.0001 0.16 (0.07-0.42) 0.0001
   0.56-1 1 1
LNR=lymph node ratio; DFS=disease-free survival; DSS=disease-specific survival; HR=hazard ratio; CI=confidence interval; LVI=lymphovascular invasion; ER=estrogen 
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Table 4. Disease-free survival and disease-specific survival rate by 
lymph node ratio in each stage
No. of 
patients
10-yr Kaplan-Meier estimates±SE (%)
10-yr DFS 10-yr DSS
Stage II
   LNR
      0-0.25 112 72.9±4.5 77.9±4.2
      0.26-0.55     5   60.0±21.9   80.0±17.9
      0.56-1     1   0.0±0.0   0.0±0.0
      p-value 0.0392 0.1286
Stage III
   LNR
      0-0.25   66 72.3±5.6 71.4±6.1
      0.26-0.55   59 48.8±6.8 55.1±6.8
      0.56-1   87 28.0±4.9 33.0±5.3
      p-value <0.0001 <0.0001
pN1
   LNR
      0-0.25 129 71.8±4.2 76.6±4.0
      0.26-0.55     9   41.7±17.3   64.8±16.5
      0.56-1     2   0.0±0.0   0.0±0.0
      p-value 0.0001 0.0015
pN2
   LNR
      0-0.25   48 76.9±6.1 74.1±7.0
      0.26-0.55   41 49.6±8.1 56.3±8.1
      0.56-1   19   26.3±10.1   28.9±11.0
      p-value 0.0001 0.0002
pN3
   LNR
      0-0.25     1   0.0±0.0   0.0±0.0
      0.26-0.55   14   57.1±13.2   54.4±14.0
      0.56-1   67 28.9±5.7 35.1±6.1
      p-value 0.3616 0.4486
SE=standard error; DFS=disease-free survival; DSS=disease-specific survival; 
LNR=lymph node ratio.
population data, the importance of LNR has been shown for 
many cancer sites including the esophagus [21], colon [22], 
and corpus uteri [23]. In breast cancer there is growing evidence 
establishing the prognostic value of the LNR. Woodward et al. 
[5] conducted a systematic review of 24 reports published be-
tween 1994 and 2005 that implicate a prognostic role for the 
LNR, using both prospective and retrospectively collected data 
sets. The LNR was confirmed to be superior to the number of 
involved nodes as a prognostic indicator.
However, there is no clear consensus about the cutoff points 
that are required for a staging classification. The cutoff points 
to classify patients into two groups are 0.2 [7,10] or 0.25 [8], 
which were most significant for recurrence or overall survival. 
Several authors divided patients into three groups using cut-
offs such as 0.33/0.67 [11], 0.1/0.5 [4] or 0.25/0.5 [9]. The pro-
cess for deciding such cutoff points was not described in their 
articles. Vinh-Hung et al. [6] identified 1,829 node-positive 
breast cancer patients from the Geneva Cancer Registry. They 
identified the cutoff points of 0.2 and 0.65, which were validated 
by a bootstrap procedure. They suggested that the LNR should 
be considered as an alternative to pN staging because of the 
stronger statistical power to predict breast cancer-specific sur-
vival as well as considering that there is, in practice, wide vari-
ation in axillary dissection and node examination in heteroge-
neous patient populations.
Ratio-based prediction is an emerging issue even in the field 
of SLNB. A recent Australian study highlights the predictive role 
of the involved SN ratio that has the largest effect on the odds 
of finding further axillary nodal involvement [24]. Barranger 
et al. [25] reported that the ratio of involved SN, primary tumor 
size and the size of the SN metastasis were independently pre-
dictive of non-SN involvement. Using the concept of the SN 
ratio, the predictors of tumor involvement in the remaining 
axillary nodes in SN positive breast cancers are being widely 
investigated. It is expected that more studies will demonstrate 
the prognostic impact of the SN ratio in the case of SLNB for 
early stage breast cancer.
Accurate staging information is very important for both     
patients and clinicians to assess the prognosis and to make   
informed decisions about breast cancer treatment. Our results 
are consistent with the findings of recent studies evaluating the 
relationship between LNR and survival for node positive breast 
cancer [4-10]. This study may be differentiated from other stud-
ies due to the subgroup analyses in each TNM stage and pN 
stage to evaluate the impact of the LNR. However, the present 
study has several shortcomings. First, the patient population 
was identified from the database of the department of radia-
tion oncology and a few patients who had not received post-
operative radiotherapy after MRM could not be included to 
the analysis. Second, it was a retrospective study that the sur-
gical procedures and the methods of pathological examination 
could not be unified as in the prospective studies. Systematic 
LNR analysis from multi-institutional randomized patient data 
with validation in similar independent data sets is needed to 
define clearly the utility of LNR.
This study supports the hypothesis that, in patients with inva-
sive breast cancer with positive axillary nodes, the ratio between 
the number of positive nodes and total numbers of dissected 
nodes is the most powerful predictor of the risk of recurrence 
and survival. The LNR showed a stronger association with DFS 
and DSS than did pN staging. The calculation of the LNR is easy 
and assists in the choice of adjuvant treatment and evaluation 
of the prognosis in the clinical setting. A future staging system 
should incorporate the LNR for accurate staging of axillary nodes 
to overcome the confusion arising from the number of dissect-
ed nodes in this era of minimally invasive axillary surgery.212   Ji-Yoon Kim, et al.
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